⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RAPT News
RAPT Therapeutics, Inc. Common Stock
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
globenewswire.com
RAPT
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
globenewswire.com
RAPT
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
globenewswire.com
RAPT
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
globenewswire.com
RAPT